Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
115M
-
Number of holders
-
200
-
Total 13F shares, excl. options
-
79.4M
-
Shares change
-
-7.35M
-
Total reported value, excl. options
-
$1.16B
-
Value change
-
-$125M
-
Put/Call ratio
-
2.1
-
Number of buys
-
104
-
Number of sells
-
-86
-
Price
-
$14.61
Significant Holders of Coherus Oncology, Inc. - Common Stock (CHRS) as of Q1 2021
232 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock as of Q1 2021.
Coherus Oncology, Inc. - Common Stock (CHRS) has 200 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 79.4M shares
of 115M outstanding shares and own 68.83% of the company stock.
Largest 10 shareholders include BlackRock Inc. (11.2M shares), Temasek Holdings (Private) Ltd (7.38M shares), JPMORGAN CHASE & CO (5.2M shares), STATE STREET CORP (4.83M shares), PERCEPTIVE ADVISORS LLC (4.7M shares), VANGUARD GROUP INC (4.26M shares), ALLIANCEBERNSTEIN L.P. (4.2M shares), Kohlberg Kravis Roberts & Co. L.P. (3.04M shares), Aristotle Capital Boston, LLC (2.1M shares), and GOLDMAN SACHS GROUP INC (1.33M shares).
This table shows the top 200 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.